相似文献
1
BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment.
Thorax. 2005 Oct;60(10):800-5. doi: 10.1136/thx.2005.046797. Epub 2005 Jul 29.
2
Assessing risk and managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNFalpha treatment.
Cytokine. 2004;28(4-5):179-81. doi: 10.1016/j.cyto.2004.07.013.
3
British Thoracic Society (BTS) recommendations for assessing risk and managing tuberculosis in patients due to start anti-TNF-{alpha} treatments.
Rheumatology (Oxford). 2005 Oct;44(10):1205-6. doi: 10.1093/rheumatology/kei103.
4
5
Hepatotoxicity and antituberculosis therapy: time to revise UK guidance?
Thorax. 2009 Oct;64(10):918. doi: 10.1136/thx.2009.115469.
6
Supplement on future research in tuberculosis. Prospects and priorities for elimination. Endorsement of the American Thoracic Society Board of Directors in March 1986.
Am Rev Respir Dis. 1986 Aug;134(2):401-23.
7
Tuberculosis screening in prescribers of anti-tumor necrosis factor therapy in the European Union.
Int J Tuberc Lung Dis. 2012 Sep;16(9):1168-73. doi: 10.5588/ijtld.12.0029. Epub 2012 Jul 12.
8
Evaluating the use of the interferon-γ response to Mycobacterium tuberculosis-specific antigens in patients with psoriasis prior to antitumour necrosis factor-α therapy: a prospective head-to-head cross-sectional study.
Br J Dermatol. 2013 May;168(5):1012-8. doi: 10.1111/bjd.12176.
9
[Liver and antitubercular drug therapy].
Rev Fac Cienc Med Cordoba. 1974 Jan-Mar;32(1):19-36.
10
Adverse drug reactions in TB therapy: risks and recommendations.
Geriatrics. 1982 Jul;37(7):61-8.
引用本文的文献
1
Pulmonary Complications in Connective Tissue Disease-Associated Interstitial Lung Disease.
Clin Respir J. 2025 Aug;19(8):e70116. doi: 10.1111/crj.70116.
2
Risk of Latent Tuberculosis Infection Reactivation in Patients Treated with Tumor Necrosis Factor Antagonists: A Five-Year Retrospective Study.
Trop Med Infect Dis. 2025 Jul 7;10(7):190. doi: 10.3390/tropicalmed10070190.
3
Diagnostic dilemma of a new endobronchial lesion in a patient on anti-tuberculosis regimen: unveiling tuberculosis immune reconstitution inflammatory syndrome.
BMC Infect Dis. 2025 May 2;25(1):648. doi: 10.1186/s12879-025-11047-6.
4
Concurrent Psoriatic Arthritis and Ankylosing Spondylitis in a Middle-Aged Man: A Case Report With Peripheral Joint Functional and Quality of Life Assessment.
Cureus. 2025 Feb 28;17(2):e79826. doi: 10.7759/cureus.79826. eCollection 2025 Feb.
5
Raising the bar in ulcerative colitis management.
Therap Adv Gastroenterol. 2024 Nov 24;17:17562848241273066. doi: 10.1177/17562848241273066. eCollection 2024.
6
Choosing Therapy for Moderate to Severe Crohn's Disease.
J Can Assoc Gastroenterol. 2023 Sep 22;7(1):1-8. doi: 10.1093/jcag/gwad023. eCollection 2024 Feb.
7
Evaluation of serious infections, including Mycobacterium tuberculosis, during treatment with biologic disease-modifying anti-rheumatic drugs: does line of therapy matter?
Rheumatology (Oxford). 2024 Jul 1;63(7):1957-1964. doi: 10.1093/rheumatology/kead515.
8
Acute heart failure as an adverse event of tumor necrosis factor inhibitor therapy in inflammatory bowel disease: A review of the literature.
World J Cardiol. 2023 May 26;15(5):217-228. doi: 10.4330/wjc.v15.i5.217.
9
Correlation between tuberculosis-specific interferon-γ release assay and intrathoracic calcification: A cross-sectional study.
PLoS One. 2022 Jul 6;17(7):e0270785. doi: 10.1371/journal.pone.0270785. eCollection 2022.
10
Review article: latent tuberculosis in patients with inflammatory bowel diseases receiving immunosuppression-risks, screening, diagnosis and management.
Aliment Pharmacol Ther. 2022 Jul;56(1):6-27. doi: 10.1111/apt.16952. Epub 2022 May 20.
本文引用的文献
1
High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy.
Clin Gastroenterol Hepatol. 2004 Apr;2(4):309-13. doi: 10.1016/s1542-3565(04)00060-6.
2
Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy.
Arthritis Rheum. 2004 Feb;50(2):372-9. doi: 10.1002/art.20009.
3
Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management.
Lancet Infect Dis. 2003 Mar;3(3):148-55. doi: 10.1016/s1473-3099(03)00545-0.
4
Risk factors for hepatotoxicity associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection: experience from three public health tuberculosis clinics.
Int J Tuberc Lung Dis. 2002 Nov;6(11):995-1000.
5
Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis.
Am J Respir Crit Care Med. 2003 Mar 15;167(6):824-7. doi: 10.1164/rccm.200209-998OC. Epub 2002 Nov 21.
6
Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial.
Ann Intern Med. 2002 Oct 15;137(8):640-7. doi: 10.7326/0003-4819-137-8-200210150-00007.
7
Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.
N Engl J Med. 2001 Oct 11;345(15):1098-104. doi: 10.1056/NEJMoa011110.
8
Cytokine pathways and joint inflammation in rheumatoid arthritis.
N Engl J Med. 2001 Mar 22;344(12):907-16. doi: 10.1056/NEJM200103223441207.
9
Tuberculosis at the end of the 20th century in England and Wales: results of a national survey in 1998.
Thorax. 2001 Mar;56(3):173-9. doi: 10.1136/thorax.56.3.173.
10
New drugs for the treatment of rheumatoid arthritis.
Am J Health Syst Pharm. 2000 Feb 1;57(3):225-34. doi: 10.1093/ajhp/57.3.225.
Zotero 插件